Q-omics provides the consensus-scored ZNF454 profile across patient tissues and cancer cell-line models. ZNF454 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF454 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, ZNF454 RNA expression shows 18,218 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KICH, and GBM as cancer lineages where ZNF454 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF454 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF454 survival associations across molecular data types. ZNF454 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF454 RNA expression–survival associations across cancer types. High ZNF454 expression shows unfavorable associations in COAD and ESCA, but favorable associations in UVM, KIRC, UCS and MESO. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF454 RNA expression.
This table summarizes ZNF454 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF454. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF454 shows lower tumor expression in KICH, KIRC, COAD, UCEC, BRCA and LUSC. The KICH box plot shows higher ZNF454 RNA expression in normal versus tumor tissue (log2 FC = −1.358, t-test p < 0.001).
This table shows molecular features associated with ZNF454 in patient tissues and cancer cell lines. In patient samples, ZNF454 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF454 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
